Navigation Links
MD Anderson Cancer Center joins Actinium Pharmaceuticals' (API) Multicenter Actimab-A Trial
Date:9/12/2012

ltiple doses of treatment.  The population for this study will be patients with newly diagnosed AML who are over the age of 60 years, an age in which many chemotherapy regimens are not tolerated.  In other published studies in AML, newly diagnosed patients had better responses than relapsed patients.

About Actimab-A

Actimab-A is a drug candidate construct made using Actinium Pharmaceuticals' proprietary patented technology for arming monoclonal antibodies with alpha emitters actinium 225 and bismuth 213.  Antibodies are used as high precision delivery systems that bring powerful alpha emitters into or immediately next to targeted cancer cells.  Actimab-A consists of the Lintuzumab monoclonal antibody and actinium 225.

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed.  The technology was first developed by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center. 

Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a Newark, New Jersey based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

For more information:

Visit our web site www.actiniumpharmaceuticals.com or contact:

Media:
Dennis S. Dobson Jr., 203-258-0159
Email: '/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
2. MarketsandMarkets: Lung Cancer Drugs Market in G7 Countries Worth $13 Billion by 2020
3. Virobays Spectrum-Selective Cathepsin Inhibitor Shows Efficacy in Bone Cancer Model
4. Biocept and Academic Collaborators to Present Posters at San Antonio Breast Cancer Symposium on Circulating Tumor Cells (CTCs)
5. NKTR-102 Demonstrates Synergistic Anti-Tumor Activity in Combination with Pegylated Liposomal Doxorubicin in Platinum-Resistant Ovarian Cancer
6. Members of Congress, Cancer Experts Address Impact of Genetic Testing on Cancer
7. Masaryk Memorial Cancer Institute Reduces Losses and Administrative Overhead With Ekahau RTLS
8. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
9. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
10. New research points to benefits of innovative cobas® HPV test for primary screening as Englands cervical cancer screening programme includes the test in current HPV "triage" rollout
11. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... , May 24, 2013 Die ... – Bei der englischen Version ... , 91 % der Teilnehmer einer groß angelegten Asthmaumfrage ... % laut GINA [*] -Definition [1] als kontrolliert ... mit Asthma generell einer von vier Denkweisen zugeordnet werden ...
(Date:5/23/2013)... , May 23, 2013  BioScrip, Inc. (NASDAQ: ... present at the Jefferies 2013 Global Healthcare Conference to ... New York. Richard Smith ... Hai Tran , Chief Financial Officer, will present ... Daylight Time.   About BioScrip BioScrip, ...
(Date:5/23/2013)... 23, 2013 Patheon Inc ., ... to the global pharmaceutical industry, will host a complimentary ... to Testing” on Tuesday, June 4, 2013 at 11 ... are required to comply with regulations for cleaning validation. ... limited scientific underpinning and little evaluation of risk. ...
(Date:5/23/2013)... CA (PRWEB) May 23, 2013 The ... encourage all types of inventions. They focus on learning ... noticing this community gravitate toward bringing their ideas to ... DIY Biology Movement, works on making projects using biology. ... DNA of plants to make them glow with bioluminescence ...
Breaking Biology Technology:Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7Patheon to Present on “Cleaning Validation: Science, Risk and Novel Approaches to Testing” 2Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2
... in demand for nanotech tools in the coming years, ... New York consulting firm that focuses on nanotechnology. , ... that sales of nanotech tools could double to $1.1 ... on remarkable applications ranging from computer displays to cancer ...
... - Stratatech Corp. has received a $154,000 ... Aging , a division of the National Institutes of ... products for the use in the treatment of chronic skin ... pressure ulcers. , ,It is estimated that in the United ...
... MILWAUKEE -- With the new school semester just ... Marquette University, however, is hoping that illegal Internet downloading ... is the first university working with the Business ... including, Microsoft, Apple and Adobe. The BSA's Define ...
Cached Biology Technology:Corporate clients will dominate surge in nanotech tool demand, study projects 2Corporate clients will dominate surge in nanotech tool demand, study projects 3Marquette targets illegal downloading 2Marquette targets illegal downloading 3
(Date:5/24/2013)... and other non-coding RNAs are small molecules that ... recent years they have emerged as disease biomarkers. ... origin for cancers of unknown primary origin, determine ... but clinically tractable, diagnostic methods for monitoring miRNA ... In this issue of the Journal of ...
(Date:5/24/2013)... have focused among other factors on drugs that ... the accumulation of A-beta that causes the known plaques in ... of A-beta is APP. Alessia Soldano and Bassem Hassan (VIB/KU ... the fruit-fly version of APP in the brain ... "We have discovered that APPL ensures that brain cells form ...
(Date:5/23/2013)... , Automated conserved noncoding sequence (CNS) discovery reveals ... , Within the genome of each species, there ... change in position and sequence over millions of years, ... these evolutionarily stable sequences, so-called conserved noncoding sequences (CNSs), ... or the condensation of chromosomes, but the function of ...
Breaking Biology News(10 mins):A new strategy required in the search for Alzheimer's drugs? 2Frontiers news briefs: May 23 2Frontiers news briefs: May 23 3
... 27 ViroPharma Incorporated (Nasdaq: VPHM ) ... Phase 2 study to evaluate the safety, and pharmacokinetics ... (C1 esterase inhibitor [human)] in 24 adolescents and adult ... the U.S. Food and Drug Administration in October ...
... , XIANYANG, China ... Inc. (Nasdaq: BSPM ) ("Biostar" or "the ... B medicine,Xin Aoxing Oleanolic Acid Capsule ("Xin Aoxing"), ... new advertising approval from,Shaanxi State Food and Drug ...
... April 27 Mondre Energy, Inc. (MEI), a leading energy ... to address a wide range of energy issues on behalf of the ... Research Program works to ensure that Maryland meets its electricity ... , , ...
Cached Biology News:ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 2ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 3ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 4ViroPharma Announces Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze(TM) (C1 Esterase Inhibitor [Human]) 5Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 2Biostar Pharmaceuticals, Inc. Receives New Advertising Approval from Shaanxi SFDA for Marketing Xin Aoxing Capsule 3Mondre Energy Partnering with Exeter Associates to Address Energy Issues in Maryland 2
RatTRAPTM Assay is a solid-phase immunofixed enzyme activity assay for the determination of osteoclast-derived TRACP 5b activity in rat serum....
... Preparation contains a unique β-agarose digesting enzyme ... of intact DNA and RNA from low ... in TAE, TBE, MOPS, or phosphate buffers. ... the TAE, TBE, MOPS, and phosphate electrophoresis ...
... Terminal deoxynucleotidyl transferase (TdT) is an ... in cortical thymocytes and minor subpopulation of ... enzyme and increased numbers of TdT cells ... lymphoblastic leukaemias and lymphomas. Presence of TdT ...
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
Biology Products: